The immunostimulatory effects of retinoblastoma cell supernatant on dendritic cells. Issue 4 (4th March 2014)

• Record Type: Journal Article
• Authors: Ma, Juan; Han, Huamin; Ma, Li; Liu, Changzhen; Xue, Xin; Ma, Pan; Li, Xiaomei; Tao, Hua
• Is Part Of: Protein & cell. Volume 5:Issue 4(2014)
• Page Start: 307
• Page End: 316
• Publication Date: 2014-03-04
• Subjects: retinoblastoma -- dendritic cell -- anti-tumor immunity -- immunotherapy; Proteins -- Periodicals; Cells -- Periodicals; Cytology -- Periodicals; 572.6
• DOI: 10.1007/s13238-014-0029-0
• Languages: English
• ISSNs: 1674-800X

Abstract

Abstract: Dendritic cells (DCs) are crucial for the induction and maintenance of tumor-specific immune responses. Studies have shown that tumor-associated DCs are immunosuppressed in some human tumors. However, phenotype and function of DCs in retinoblastoma (RB) remain unclear. RB cell supernatant (RBcs) was used to treat DCs in vitro to explore the effect of RB cells on DCs. DCs were generated from peripheral blood mononuclear cells of healthy donors. On day 5 of culture, DCs were treated with RBcs for 24 h, and then purified using magnetic beads. The maturation of DCs was induced by TNF-α or LPS. After treatment with RBcs, expression of co-stimulatory molecules CD80 and CD86 was elevated in DCs, accompanied by increased production of IL-12p70, TNF-α, IL-6, IL-1β, and IL-8 but decreased production of IL-10. RBcs neither inhibited DC maturation nor promoted DC apoptosis. Moreover, RBcs-exposed DCs stimulated allogenetic T cell proliferation and T cell-derived cytokine production. These results indicate that RBcs can improve DCs' antigen presenting function and capability to activate T cells, suggesting that RB cells may have an immunostimulatory effect on DCs, and DC-based immunotherapy may be adopted in the treatment of RB.